CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, Inc. ("Dimension" or the "Company"), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced the election of George Migausky to the Company's Board of Directors. Mr. Migausky brings more than 30 years of senior financial management experience with high-growth life science and technology companies. His election to Dimension's Board is effective immediately, and he will chair the newly established audit committee.